Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216627 · ClinicalTrials.gov registry record
COVID-19 Screening Program
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 61
- Enrollment target
NCT05216627: Completed study, sponsored by University of Pennsylvania.
NCT05216627 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216627 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
Study Summary
In view of the recent COVID surge and difficulties in obtaining testing, we aim to increase Point of Care (POC) testing, whereby University of Pennsylvania (Penn) faculty, staff, and trainees who are working in person at Perelman School of Medicine (PSOM) laboratories can self-test. The purpose of this study is to evaluate the implementation of this POC testing program. We will not be collecting any samples as part of this study. This will ensure that individuals can rapidly identify if they have COVID-19 while balancing use, acceptability, appropriateness, and feasibility. We will start with a pilot phase whereby we will evaluate the implementation of a POC version of COVID-19 screening program that will coordinate several existing systems at the University of Pennsylvania including voluntary, self-administered saliva-based viral testing. We will pilot this program to a small cohort of PSOM labs and then test implementation of the self-testing of the POC version of COVID-19 screening across all PSOM labs for those who wish to participate. All results will be self-reported and will not be used to validate any tests or support any future approval from the FDA. No data from this study will go into the participants' Electronic Medical Record (EMR).
Primary Outcome
How often they use the POC screening program
Interventions
- DIAGNOSTIC_TEST Self-administered saliva-based viral testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2022-07-01 |
What the finished NCT05216627 record still lists
NCT05216627 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Self-administered saliva-based viral testing is the first listed.
NCT05216627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05216627 about?
NCT05216627 is a clinical study titled "COVID-19 Screening Program". In view of the recent COVID surge and difficulties in obtaining testing, we aim to increase Point of Care (POC) testing, whereby University of Pennsylvania (Penn) faculty, staff, and trainees who are working in person at Perelman School of Medicine (PSOM) laboratories can self-test. The purpose of t...
What is the current status of trial NCT05216627?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2022-02-07. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT05216627?
The interventions under investigation include: Self-administered saliva-based viral testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05216627?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI